Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914552 | 0.84 | RAB9A (0.68) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL13144514 | 0.84 | MAPT (0.70) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL11004517 | 0.83 | MAPT (0.46) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL4717848 | 0.83 | RAB9A (0.62) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL9454202 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL163667 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL1438508 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL285573 | 0.82 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL3001536 | 0.81 | RAB9A (0.64) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL13075225 | 0.81 | RAB9A (0.64) | RAB9AMAPTNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-3831839-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-07-26 | — | — | EP | disclosed |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| EP-3831839-A2 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | ViiV Healthcare UK (No.5) Limited (GB) | 2021-06-09 | — | — | EP | disclosed |
| CN-109153700-B | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV保健英国第五有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3411381-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| CN-109153700-A | The triterpene compound that C-3 and C-17 as HIV-1 inhibitor are modified | VIIV保健英国第五有限公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-3411381-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134596-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | RAB9A 3126/4885MAPT 2571/4885NPC1 864/4885 |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | RAB9A 3126/4885MAPT 2571/4885NPC1 864/4885 |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | RAB9A 3126/4885MAPT 2571/4885NPC1 864/4885 |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | RAB9A 3126/4885MAPT 2571/4885NPC1 864/4885 |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | RAB9A 3126/4885MAPT 2571/4885NPC1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.